Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal Adenocarcinoma

Caitlin C. Murphy, Arlene M. Correa, Jaffer A. Ajani, Ritsuko U. Komaki, James W. Welsh, Stephen G. Swisher, Wayne L. Hofstetter

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Experience with neoadjuvant chemoradiation (CXRT) has raised questions regarding the additional benefit of surgery after locally advanced esophageal adenocarcinoma patients achieve a clinical response to CXRT. We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy. Methods: We identified 143 clinical stage III esophageal adenocarcinoma patients that were eligible for trimodality therapy. All patients successfully completed neoadjuvant CXRT and were considered appropriate candidates for resection. Patients that were medically inoperable were excluded. Cox regression models were used to identify significant predictors of survival. Results: Among the 143 patients eligible for surgery after completing CXRT, 114 underwent resection and 29 did not. Poorly differentiated tumors (HR = 2.041, 95% CI = 1.235-3.373) and surgical resection (HR = 0.504, 95% CI = 0.283-0.899) were the only independent predictors of OS. Patients treated with surgery had a 50 and 54 % risk reduction in overall and cancer-specific mortality, respectively. Median OS (41.2 vs. 20.3 months, p = 0.012) and DFS (21.5 vs. 11.4 months, p = 0.007) were significantly improved with the addition of surgery compared to definitive CXRT. Conclusions: Surgery provides a significant survival benefit to trimodality-eligible esophageal adenocarcinoma patients with locally advanced disease.

Original languageEnglish (US)
Pages (from-to)1359-1369
Number of pages11
JournalJournal of Gastrointestinal Surgery
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2013

Fingerprint

Adenocarcinoma
Therapeutics
Disease-Free Survival
Esophagectomy
Survival
Risk Reduction Behavior
Proportional Hazards Models
Neoplasms
Mortality

Keywords

  • Esophageal adenocarcinoma
  • Esophagectomy
  • Neoadjuvant chemoradiation
  • Selective surgery
  • Trimodality therapy

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal Adenocarcinoma. / Murphy, Caitlin C.; Correa, Arlene M.; Ajani, Jaffer A.; Komaki, Ritsuko U.; Welsh, James W.; Swisher, Stephen G.; Hofstetter, Wayne L.

In: Journal of Gastrointestinal Surgery, Vol. 17, No. 8, 01.08.2013, p. 1359-1369.

Research output: Contribution to journalArticle

Murphy, Caitlin C. ; Correa, Arlene M. ; Ajani, Jaffer A. ; Komaki, Ritsuko U. ; Welsh, James W. ; Swisher, Stephen G. ; Hofstetter, Wayne L. / Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal Adenocarcinoma. In: Journal of Gastrointestinal Surgery. 2013 ; Vol. 17, No. 8. pp. 1359-1369.
@article{7fa36dd843fa4b8885041d31b8010ce6,
title = "Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal Adenocarcinoma",
abstract = "Background: Experience with neoadjuvant chemoradiation (CXRT) has raised questions regarding the additional benefit of surgery after locally advanced esophageal adenocarcinoma patients achieve a clinical response to CXRT. We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy. Methods: We identified 143 clinical stage III esophageal adenocarcinoma patients that were eligible for trimodality therapy. All patients successfully completed neoadjuvant CXRT and were considered appropriate candidates for resection. Patients that were medically inoperable were excluded. Cox regression models were used to identify significant predictors of survival. Results: Among the 143 patients eligible for surgery after completing CXRT, 114 underwent resection and 29 did not. Poorly differentiated tumors (HR = 2.041, 95{\%} CI = 1.235-3.373) and surgical resection (HR = 0.504, 95{\%} CI = 0.283-0.899) were the only independent predictors of OS. Patients treated with surgery had a 50 and 54 {\%} risk reduction in overall and cancer-specific mortality, respectively. Median OS (41.2 vs. 20.3 months, p = 0.012) and DFS (21.5 vs. 11.4 months, p = 0.007) were significantly improved with the addition of surgery compared to definitive CXRT. Conclusions: Surgery provides a significant survival benefit to trimodality-eligible esophageal adenocarcinoma patients with locally advanced disease.",
keywords = "Esophageal adenocarcinoma, Esophagectomy, Neoadjuvant chemoradiation, Selective surgery, Trimodality therapy",
author = "Murphy, {Caitlin C.} and Correa, {Arlene M.} and Ajani, {Jaffer A.} and Komaki, {Ritsuko U.} and Welsh, {James W.} and Swisher, {Stephen G.} and Hofstetter, {Wayne L.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/s11605-013-2223-4",
language = "English (US)",
volume = "17",
pages = "1359--1369",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal Adenocarcinoma

AU - Murphy, Caitlin C.

AU - Correa, Arlene M.

AU - Ajani, Jaffer A.

AU - Komaki, Ritsuko U.

AU - Welsh, James W.

AU - Swisher, Stephen G.

AU - Hofstetter, Wayne L.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background: Experience with neoadjuvant chemoradiation (CXRT) has raised questions regarding the additional benefit of surgery after locally advanced esophageal adenocarcinoma patients achieve a clinical response to CXRT. We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy. Methods: We identified 143 clinical stage III esophageal adenocarcinoma patients that were eligible for trimodality therapy. All patients successfully completed neoadjuvant CXRT and were considered appropriate candidates for resection. Patients that were medically inoperable were excluded. Cox regression models were used to identify significant predictors of survival. Results: Among the 143 patients eligible for surgery after completing CXRT, 114 underwent resection and 29 did not. Poorly differentiated tumors (HR = 2.041, 95% CI = 1.235-3.373) and surgical resection (HR = 0.504, 95% CI = 0.283-0.899) were the only independent predictors of OS. Patients treated with surgery had a 50 and 54 % risk reduction in overall and cancer-specific mortality, respectively. Median OS (41.2 vs. 20.3 months, p = 0.012) and DFS (21.5 vs. 11.4 months, p = 0.007) were significantly improved with the addition of surgery compared to definitive CXRT. Conclusions: Surgery provides a significant survival benefit to trimodality-eligible esophageal adenocarcinoma patients with locally advanced disease.

AB - Background: Experience with neoadjuvant chemoradiation (CXRT) has raised questions regarding the additional benefit of surgery after locally advanced esophageal adenocarcinoma patients achieve a clinical response to CXRT. We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy. Methods: We identified 143 clinical stage III esophageal adenocarcinoma patients that were eligible for trimodality therapy. All patients successfully completed neoadjuvant CXRT and were considered appropriate candidates for resection. Patients that were medically inoperable were excluded. Cox regression models were used to identify significant predictors of survival. Results: Among the 143 patients eligible for surgery after completing CXRT, 114 underwent resection and 29 did not. Poorly differentiated tumors (HR = 2.041, 95% CI = 1.235-3.373) and surgical resection (HR = 0.504, 95% CI = 0.283-0.899) were the only independent predictors of OS. Patients treated with surgery had a 50 and 54 % risk reduction in overall and cancer-specific mortality, respectively. Median OS (41.2 vs. 20.3 months, p = 0.012) and DFS (21.5 vs. 11.4 months, p = 0.007) were significantly improved with the addition of surgery compared to definitive CXRT. Conclusions: Surgery provides a significant survival benefit to trimodality-eligible esophageal adenocarcinoma patients with locally advanced disease.

KW - Esophageal adenocarcinoma

KW - Esophagectomy

KW - Neoadjuvant chemoradiation

KW - Selective surgery

KW - Trimodality therapy

UR - http://www.scopus.com/inward/record.url?scp=84880137210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880137210&partnerID=8YFLogxK

U2 - 10.1007/s11605-013-2223-4

DO - 10.1007/s11605-013-2223-4

M3 - Article

VL - 17

SP - 1359

EP - 1369

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 8

ER -